According to Kyodo News Agency on December 11, regarding the novel coronavirus vaccine being developed by British pharmaceutical giant AstraZeneca, Kenhisamura, Japan’s health and health workers, announced at a press conference after the cabinet meeting on the 11th that the government has officially signed a contract with the company.
If put into practice, it will get 120 million yuan from next year. Supply of dose vaccines. The two sides reached a basic agreement on the supply plan in August and held continuous consultations.
According to the plan, Japan will receive 30 million doses by the end of March next year. It is envisaged that each person will be vaccinated twice, and the number of contracts is equivalent to 60 million.
The company has jointly developed a vaccine with Oxford University in the United Kingdom.
According to clinical trials, the overall average efficiency is about 70%. On the other hand, due to suspected serious side effects of participants, the clinical trial was interrupted in September, and then restarted on the grounds that “government departments confirmed that it is safe to continue to advance”.